Author + information
- Received November 11, 2009
- Accepted December 16, 2009
- Published online August 10, 2010.
- Enrico M. Zardi, MD*,* (, )
- Antonio Abbate, MD, PhD†,
- Domenico Maria Zardi, MD‡,
- Aldo Dobrina, MD§,
- Domenico Margiotta, MD*,
- Benjamin W. Van Tassel, PharmD†,
- Antonella Afeltra, MD* and
- Arun J. Sanyal, MD∥
- ↵*Reprint requests and correspondence:
Dr. Enrico M. Zardi, Università “Campus Bio-Medico,” Via Àlvaro del Portillo, Rome 200-00128, Italy
Cirrhotic cardiomyopathy is a clinical syndrome in patients with liver cirrhosis characterized by an abnormal and blunted response to physiologic, pathologic, or pharmacologic stress but normal to increased cardiac output and contractility at rest. As many as 50% of cirrhotic patients undergoing liver transplantation show signs of cardiac dysfunction, and 7% to 21% of deaths after orthotopic liver transplantation result from overt heart failure. In this review, we critically evaluate the existing literature on the pathophysiology and clinical implications of cirrhotic cardiomyopathy.
The authors have reported that they have no relationships to disclose.
- Received November 11, 2009.
- Accepted December 16, 2009.
- American College of Cardiology Foundation